research Abiraterone and spironolactone in prostate cancer: a combination to avoid 9 citations , November 2018 in “Acta Clinica Belgica” Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.
research Steroidal 5α-reductase and 17α-hydroxylase/17,20-lyase (CYP17) inhibitors useful in the treatment of prostatic diseases 51 citations , May 2013 in “The Journal of Steroid Biochemistry and Molecular Biology” Certain drugs that block specific enzymes can help treat prostate diseases.
research Editorial: Androgen-dependent diseases and their treatment December 2024 in “Frontiers in Endocrinology” Continued research and awareness are needed to improve treatments for androgen-dependent diseases.
research Recent discoveries and developments of androgen receptor based therapy for prostate cancer 17 citations , January 2015 in “MedChemComm” New treatments for prostate cancer are less toxic and show promise, but more research is needed to enhance their effectiveness and reduce side effects.
research HSD3B1 Genotypes Conferring Adrenal-Restrictive and Adrenal-Permissive Phenotypes in Prostate Cancer and Beyond 30 citations , July 2019 in “Endocrinology” Certain HSD3B1 gene types are linked to worse prostate cancer outcomes and affect treatment response and other health conditions.